Glycated Hemoglobin as a Marker of Dyslipidemia in Type II Diabetic Patients


R. Arora
B. Thakurdas


Background: Diabetes is an important public health problem and leading cause of cardiovascular problems its early detection and good glycemic control can reduce the complications associated with the disease.Objective: This was a prospective study planned to evaluate the relationship of glycated haemoglobin (HbA1c) and lipid profile in type II diabetic Punjabi male population.Material and Methods: A total of 200 diabetes type II patient ranging from age group of 30 to 70 years were included in the study after taking a preinformed written consent. The glycated haemoglobin (HbA1c) and lipid profile were performed on fully automated analyzers. The statistical analysis was done by using SPSS statistics and correlation among HbA1c and lipid profile of type II Diabetic patients was established.Results: The mean HbA1c was in the range of 7.54 ± 1.24 %. There were 61% subjects with high total cholesterol (TC) levels and 96% were with raised LDL levels. The 68% of the subjects were having lower HDL level. HbA1c demonstrated significant positive relationship with total cholesterol, TC (r = 0.995), triglyceride, TG (r = 0.997), high density lipoprotein cholesterol, HDL-C (r = -0.940) and with low density lipoprotein cholesterol, LDL-C (r = 0.993).Conclusion: The study concluded that HbA1c apart from acting as important diagnostic marker for glycemic control can also be used as a positive predictor of dyslipidemia in type 2 diabetics.


How to Cite
Arora, R., & Thakurdas, B. (2016). Glycated Hemoglobin as a Marker of Dyslipidemia in Type II Diabetic Patients. International Journal of Medical and Dental Sciences, 1164–1170.


  1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–53.
  2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4–14.
  3. Zimmet P, Alberti KGMM. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782–7.
  4. Motala AA, Omar MAK, Pirie FJ. Epidemiology of type 1 and type 2 diabetes in Africa. Journal of Cardiovascular Risk 2003; 10(2):77–83.
  5. Engelgau MM, Geiss LS, Saaddine JB, Stephanie MB, Edward WG, Edward FT, et al. The evolving diabetes burden in the United States. Annals of Internal Medicine 2004; 140(11):945–50.
  6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9):1414–31.
  7. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111:1448– 54.
  8. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769–78.
  9. Fox CS, Pencina MJ,Meigs JB, Vasan RS, Levitsky YS, D’Augistino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006; 113:2914–8.
  10. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5): 1047–53.
  11. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013.
  12. World Health Organization Study Group. Diabetes Mellitus: WHO Technical Report, Series 727. Geneva: World Health Organization, 1985.
  13. Magliano DJ, Zimmet P, Shaw JE. Classification of diabetes mellitus and other categories of glucose intolerance. In: Defronzo RA, Ferrrannini E, Albert KGMM, Zimmet P, editors. International Textbook of Diabetes Mellitus 4th ed. USA: Wiley Blackwell; 2015.p.3-16.
  14. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. In Albert KGMM, Zimmet P, DeFronzo RA, editors. International Textbook of Diabetes Mellitus, 2nd ed. Chichester: Wiley; 1997. p. 635-712.
  15. DCCT Study Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; Sep 30; 329(14):977–86.
  16. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327–34.
  17. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 2004; 21(7):657–65.
  18. International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327–34.
  19. Greci Laura S, Kailasam Mala. Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia Diabetes Care 2003; 26(4):1064–8.
  20. British Diabetic Association. Recommendations for the management of diabetes in primary care. London: BDA, 1993.
  21. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y,Endo G, Kambe H. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 2009; 32:644–6.
  22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2011; 34:S62–9.
  23. Shaw JE, d Emden MC, Goodall I. Is Australia ready to use glycated haemoglobin for the diagnosis of diabetes? Med J Aust 2011; 195:7–8.
  24. Davidson MB. Diagnosing diabetes with glucose criteria: worshiping a false God. Diabetes Care 2011; 34:524–6.
  25. Day A. HbA1c and diagnosis of diabetes. The test has finally come of age. Ann Clin Biochem 2012; 49:7–8.
  26. Malkani S, Mordes JP. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. Am J Med 2011; 124:395–401.
  27. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011; 34:518–23.
  28. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32:2027–32.
  29. Grundy SM. Multifactorial causation of obesity: implications for prevention. Am J Clin Nutr l 1998; 67:563S–72S.
  30. Lamarche, B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Despres JP. Fasting insulin and apolipoprotein B levels and lowdensity lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279(24): 1955-61.
  31. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulin-aemia and coronary heart disease. Diabetologia 1994 sep; 37(9): 948-52.
  32. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? Atheroscler Suppl 2005; 6:11-4.
  33. Selvin, E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR. Metaanalysis: glycosy-lated hemoglobin and cardiovascular disease in diabe-tes mellitus. Ann Intern Med 2004 sep21; 141(6):421-31.
  34. National Cholesterol Education Program Expert Panel. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001; 285:2486– 97.
  35. Berthold H, Gouni-Berthold I, Bestehorn K, Bohm M, Krone W. Cardiovascular risk factors in patients with type 2 in Germany. Deutsches Arzteblatt 2007; 104: A861–7.
  36. Bays HE, Bazata DD, Clark NG, Gavin JR, Green AJ, Lewis SJ, et al. Prevalence of selfreported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) BMC Public Health 2007 Oct3; (7):277.
  37. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23) BMJ 1998; 316:823–8.
  38. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 Jun 18; 99(12A):4i–20i.
  39. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811–22.
  40. Khan HA, Sobki SH, Khan SA. Association between glycemic control and serum lipid profile in type 2 diabetic patients: HbA1c predicts dyslipidemia. Clin Exp Med 2007; 7:24-9.
  41. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis risk in communities study. Diabetes Care 2006; 29:877-82.